Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRME logo PRME
Upturn stock ratingUpturn stock rating
PRME logo

Prime Medicine, Inc. Common Stock (PRME)

Upturn stock ratingUpturn stock rating
$3.44
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: PRME (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $6.89

1 Year Target Price $6.89

Analysts Price Target For last 52 week
$6.89 Target price
52w Low $1.11
Current$3.44
52w High $5.17

Analysis of Past Performance

Type Stock
Historic Profit -43.53%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 613.26M USD
Price to earnings Ratio -
1Y Target Price 6.89
Price to earnings Ratio -
1Y Target Price 6.89
Volume (30-day avg) 12
Beta 2.41
52 Weeks Range 1.11 - 5.17
Updated Date 08/29/2025
52 Weeks Range 1.11 - 5.17
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.56

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.43
Actual -0.41

Profitability

Profit Margin -
Operating Margin (TTM) -4787.18%

Management Effectiveness

Return on Assets (TTM) -47.39%
Return on Equity (TTM) -154.81%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 631248553
Price to Sales(TTM) 123.62
Enterprise Value 631248553
Price to Sales(TTM) 123.62
Enterprise Value to Revenue 127.24
Enterprise Value to EBITDA -3.1
Shares Outstanding 178274000
Shares Floating 58404386
Shares Outstanding 178274000
Shares Floating 58404386
Percent Insiders 18.19
Percent Institutions 44.28

ai summary icon Upturn AI SWOT

Prime Medicine, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Prime Medicine, Inc. was founded in 2020 by David Liu and Andrew Anzalone, pioneering prime editing, a next-generation gene editing technology. The company went public in October 2022. It focuses on developing potentially curative gene therapies for a wide range of diseases.

business area logo Core Business Areas

  • Prime Editing Technology: Development of prime editing technology platform for correcting genetic mutations.
  • Therapeutic Programs: Research and development of gene therapy programs targeting specific diseases using prime editing.
  • Licensing and Partnerships: Out-licensing prime editing technology and forming partnerships with other biotechnology and pharmaceutical companies.

leadership logo Leadership and Structure

Keith Gottesdiener, M.D., serves as the Chief Executive Officer. The company has a scientific advisory board comprised of leading experts in gene editing and related fields. Organizational structure includes research, development, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • Prime Editing Platform: A versatile gene editing technology designed to precisely correct genetic mutations at the source of disease. It has no current market share as it is still in development. Potential competitors include companies developing CRISPR-based therapies like CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (EDIT).
  • Preclinical Therapeutic Programs: Prime Medicine's pipeline includes preclinical programs targeting various genetic diseases. Market share data is not applicable at this stage. The competitive landscape is broad, encompassing companies developing gene therapies for specific indications, like Vertex Pharmaceuticals (VRTX) for certain genetic disorders.

Market Dynamics

industry overview logo Industry Overview

The gene editing industry is rapidly evolving, driven by advances in technologies like CRISPR and prime editing. It's characterized by high levels of innovation, significant investment, and increasing regulatory scrutiny. The field is competitive, with numerous companies developing gene therapies for a wide range of diseases.

Positioning

Prime Medicine is positioned as a leader in prime editing technology, which offers potential advantages over other gene editing approaches in terms of precision and versatility. Their competitive advantage lies in the capabilities of the prime editing technology itself.

Total Addressable Market (TAM)

The total addressable market for gene therapies is estimated to be in the hundreds of billions of dollars. Prime Medicine is positioned to capture a portion of this market with its prime editing technology, potentially addressing diseases currently untreatable by other gene editing methods.

Upturn SWOT Analysis

Strengths

  • Novel prime editing technology
  • Strong intellectual property position
  • Experienced leadership team
  • Significant funding and partnerships

Weaknesses

  • Technology is still early stage
  • High research and development costs
  • Reliance on prime editing success
  • Limited clinical data

Opportunities

  • Expanding therapeutic applications of prime editing
  • Partnerships with pharmaceutical companies
  • Potential for curative therapies for genetic diseases
  • Growing market for gene editing technologies

Threats

  • Competition from other gene editing technologies
  • Regulatory hurdles for gene therapies
  • Potential for off-target effects or other safety concerns
  • High cost of gene therapies and reimbursement challenges

Competitors and Market Share

competitor logo Key Competitors

  • CRSP
  • NTLA
  • EDIT

Competitive Landscape

Prime Medicine has a competitive advantage due to their prime editing technology, which is more precise and versatile than other gene editing technologies. However, CRISPR-based competitors are further along in clinical development and have a larger market share.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the company's recent founding, but has had a substantial increase in revenue with more collaborations being established.

Future Projections: Future growth is dependent on the successful development and commercialization of prime editing-based therapies. Analyst estimates are positive, but subject to the risks inherent in drug development.

Recent Initiatives: Recent initiatives include expanding their pipeline of preclinical programs, securing partnerships with pharmaceutical companies, and advancing their prime editing technology.

Summary

Prime Medicine is a pioneering gene editing company with a promising prime editing technology. While still early-stage, it possesses a strong intellectual property position and experienced leadership. Success hinges on overcoming regulatory hurdles and safety considerations. The company faces stiff competition from CRISPR-based approaches but possesses significant long-term potential within the expanding gene therapy market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Prime Medicine Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on your own research and due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Prime Medicine, Inc. Common Stock

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2022-10-20
CEO & Director Dr. Allan Reine M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 214
Full time employees 214

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.